Northern Trust
TCRX icon

Northern Trust’s TScan Therapeutics TCRX Stock Holding History

Northern Trust’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$98.4K Sell
97,448
-750
-0.8% -$801 ﹤0.01% 4112
2025
Q4 		$98.2K Sell
98,198
-350
-0.4% -$507 ﹤0.01% 4144
2025
Q3 		$179K Hold
98,548
– – ﹤0.01% 4013
2025
Q2 		$143K Sell
98,548
-231,476
-70% -$334K ﹤0.01% 4030
2025
Q1 		$455K Buy
330,024
+7,928
+2% +$17.1K ﹤0.01% 3610
2024
Q4 		$979K Sell
322,096
-2,180
-0.7% -$9.88K ﹤0.01% 3403
2024
Q3 		$1.61M Buy
324,276
+226,764
+233% +$1.37M ﹤0.01% 3125
2024
Q2 		$570K Buy
97,512
+20,552
+27% +$162K ﹤0.01% 3460
2024
Q1 		$611K Buy
76,960
+5,349
+7% +$33.6K ﹤0.01% 3494
2023
Q4 		$417K Sell
71,611
-365
-0.5% -$1.67K ﹤0.01% 3604
2023
Q3 		$184K Buy
71,976
+56,921
+378% +$133K ﹤0.01% 3844
2023
Q2 		$37.6K Buy
15,055
+905
+6% +$2.43K ﹤0.01% 4283
2023
Q1 		$29.7K Buy
14,150
+2,905
+26% +$6.9K ﹤0.01% 4375
2022
Q4 		$17.4K Buy
+11,245
New +$27.6K ﹤0.01% 4514

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Northern Trust's TCRX Position: Q1 2026 in Review

Northern Trust reduced its TScan Therapeutics (TCRX) stake by 0.76% in Q1 2026, selling an estimated $801 and leaving 97,448 shares worth $98.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4112.

Northern Trust first reported a position in TCRX in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.61M in Q3 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Northern Trust held 97,448 shares of TScan Therapeutics worth $98.4K as of Q1 2026.
  • Northern Trust sold 750 TScan Therapeutics shares in Q1 2026, an estimated $801.
  • TScan Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4112 holding.
  • Northern Trust first reported a position in TScan Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Northern Trust's TScan Therapeutics position peaked at $1.61M in Q3 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.